Anne-Sophie Chalandon works to further enhance Sanofi’s external engagement and policy shaping efforts with rare disease community. She brought a solid experience and demonstrated successes in patient advocacy and policy shaping in the rare disease space. Anne-Sophie is a major in genetic and molecular biology, holds a PhD in Business and Management from HEC Paris Business School and a master’s in health policy at Paris Sciences Po.
In her current role, she is Head of Global Rare Diseases and CGT Policy at Sanofi and Chair of the IFPMA RD group. Advancing the global agenda for people living with rare diseases is one of her main activities within IFPMA to better support access to recognition of rights for patients and their families.
She is also an active member in several Public Private Partnership such as Together4RD, Global Commission, Screen4Care and many others.
Appearances:
Pre-Congress Workshops - Tuesday 22nd October @ 14:00
WORKSHOP: The Rare Disease Action Plan – How will we implement this? [OFFSITE]
Rare diseases pose unique challenges to healthcare systems worldwide due to their low prevalence and complex treatment requirements. Traditional financing mechanisms often fail to adequately address the needs of patients with rare diseases, leading to disparities in access to treatment and care. Last June, RDI (Rare Diseases International) launched a campaign for a World Health Assembly (WHA) Resolution on Rare Diseases in 2025. RDI is launching a campaign for a World Health Assembly (WHA) Resolution on Rare Diseases in 2025.
Overall objective of the session if to discuss the different articulations needed between the several stratifications of plans, national, regional and global:
- To identify the interconnections needed
- To ensure efficiency of the system
- To avoid fragmentation of strategy and actions
- To identify the appropriate use of the resources
The session should be an active interactive session between the panelists experts and the participants.
Global, Regional, National plans – How will we implement this?
14:00 – 14:10PM - Opening Remarks from Workshop Leader – Anne-Sophie Chalandon Sanofi
14:10 – 15:10 PM - Testimony and open discussion with the floor - capture the perspective of each participant.
15:10 – 16:30PM Q&A and closing remarks
Anne-Sophie Chalandon, Head of Global Public Affairs, Rare Diseases and CGT Policies,
Sanofi
Anne-Sophie Chalandon works to further enhance Sanofi’s external engagement and policy shaping efforts with rare disease community. She brought a solid experience and demonstrated successes in patient advocacy and policy shaping in the rare disease space. Anne-Sophie is a major in genetic and...
Alexandra Heumber Perry, Chief Executive Officer,
Rare Diseases International
Alexandra Heumber Perry is the Chief Executive Officer of Rare Diseases International, the global alliance of Persons Living with a Rare Disease. She has dedicated her entire career to contribute improving healthcare policies to benefit people living with diseases, with a particular focus in...
Session led by:
Anne-Sophie Chalandon, Head of Global Public Affairs, Rare Diseases and CGT Policies,
Sanofi
Anne-Sophie Chalandon works to further enhance Sanofi’s external engagement and policy shaping efforts with rare disease community. She brought a solid experience and demonstrated successes in patient advocacy and policy shaping in the rare disease space. Anne-Sophie is a major in genetic and...
Pre-Congress Workshops - Tuesday 22nd October @ 14:00
WORKSHOP: The Rare Disease Action Plan – How will we implement this? [OFFSITE]
Rare diseases pose unique challenges to healthcare systems worldwide due to their low prevalence and complex treatment requirements. Traditional financing mechanisms often fail to adequately address the needs of patients with rare diseases, leading to disparities in access to treatment and care. Last June, RDI (Rare Diseases International) launched a campaign for a World Health Assembly (WHA) Resolution on Rare Diseases in 2025. RDI is launching a campaign for a World Health Assembly (WHA) Resolution on Rare Diseases in 2025.
Overall objective of the session if to discuss the different articulations needed between the several stratifications of plans, national, regional and global:
- To identify the interconnections needed
- To ensure efficiency of the system
- To avoid fragmentation of strategy and actions
- To identify the appropriate use of the resources
The session should be an active interactive session between the panelists experts and the participants.
Global, Regional, National plans – How will we implement this?
14:00 – 14:10PM - Opening Remarks from Workshop Leader – Anne-Sophie Chalandon Sanofi
14:10 – 15:10 PM - Testimony and open discussion with the floor - capture the perspective of each participant.
15:10 – 16:30PM Q&A and closing remarks
Anne-Sophie Chalandon, Head of Global Public Affairs, Rare Diseases and CGT Policies,
Sanofi
Anne-Sophie Chalandon works to further enhance Sanofi’s external engagement and policy shaping efforts with rare disease community. She brought a solid experience and demonstrated successes in patient advocacy and policy shaping in the rare disease space. Anne-Sophie is a major in genetic and...
Alexandra Heumber Perry, Chief Executive Officer,
Rare Diseases International
Alexandra Heumber Perry is the Chief Executive Officer of Rare Diseases International, the global alliance of Persons Living with a Rare Disease. She has dedicated her entire career to contribute improving healthcare policies to benefit people living with diseases, with a particular focus in...
Session led by:
Anne-Sophie Chalandon, Head of Global Public Affairs, Rare Diseases and CGT Policies,
sanofi
Anne-Sophie Chalandon works to further enhance Sanofi’s external engagement and policy shaping efforts with rare disease community. She brought a solid experience and demonstrated successes in patient advocacy and policy shaping in the rare disease space. Anne-Sophie is a major in genetic and...
Day 1 - Wednesday 23 October @ 14:25
Economic burden of rare diseases
Anne-Sophie Chalandon, Head of Global Public Affairs, Rare Diseases and CGT Policies,
Sanofi
Anne-Sophie Chalandon works to further enhance Sanofi’s external engagement and policy shaping efforts with rare disease community. She brought a solid experience and demonstrated successes in patient advocacy and policy shaping in the rare disease space. Anne-Sophie is a major in genetic and...
Day 1 - Wednesday 23 October @ 16:40
Panel: Evidence Assessment in rare. Why do we need a change in Paradigm. The work of HTAi RDIG
Alicia Granados, Head, Global Rare Diseases Medical Scientific Advocacy,
Sanofi
Alicia Granados, MD & PhD in Public Health from the University of Barcelona. She is a certified specialist
in respiratory medicine. Currently serving as Global Head Rare Disorder Medical Scientific Advocacy &
Insights at a big biopharma, Sanofi, where she has been heading its global...
Monica Ferrie, Chief Executive,
Genetic Support Network of Victoria
Monica has worked across the community, health, education, business and government sectors. Monica is a Council Member of Rare Disease International and currently serving the genetic, undiagnosed and rare disease communities as the Chief Executive, Genetic Support Network of Victoria (GSNV). She is ...
Sheela Upadhyaya, Life Science Advisor in Rare Diseases & Special Advisor,
Openflex Ltd
Sheela Upadhyaya is a Life Sciences Consulant and a renowed expert in rare disease with over 25 year experience in the healthcare industry.
She has broad international experience spanning, UK including Scotland and the EU5 with a record of delivering leading edge innovation for rare diseases.
...
Session led by:
Anne-Sophie Chalandon, Head of Global Public Affairs, Rare Diseases and CGT Policies,
sanofi
Anne-Sophie Chalandon works to further enhance Sanofi’s external engagement and policy shaping efforts with rare disease community. She brought a solid experience and demonstrated successes in patient advocacy and policy shaping in the rare disease space. Anne-Sophie is a major in genetic and...
Day 2 - Thursday 24 October @ 09:00
Keynote Panel: The Rare Disease Action Plan – where are we and how to integrate this from a European to a national level for real impact?
-What have we learnt from the last presidencies – how does the future of rare diseases look with Belgium and now Hungary’s leadership?
-How is each country executing their national action plan and are they involving their local policy makers?
Alexandra Heumber Perry, Chief Executive Officer,
Rare Diseases International
Alexandra Heumber Perry is the Chief Executive Officer of Rare Diseases International, the global alliance of Persons Living with a Rare Disease. She has dedicated her entire career to contribute improving healthcare policies to benefit people living with diseases, with a particular focus in...
Daniel De Vicente Corbeira, Board Member of FEDER,
FEDER
Degree in Pharmacy. Postgraduate degree in public health. Postgraduate in Management and Strategic Planning for Non-Profit Organisations. President of ASMD SpainBoard member of FEDER (Spanish Federation of Rare Diseases).Board member of Eurordis (Rare Diseases Europe).After working for more than 20 ...
Gabriella Almberg, Head of Policy and Public Affairs, Rare Diseases,
UCB
Gabriella Almberg is a Director, Global Policy Lead at UCB. She has worked at UCB since January 2021. She is a member of the multi-stakeholder Together4RD Steering Group. Previous roles include working at Novo Nordisk as Associate Policy Director, and almost 7 years at the trade...
Anne-Sophie Chalandon, Head of Global Public Affairs, Rare Diseases and CGT Policies,
Sanofi
Anne-Sophie Chalandon works to further enhance Sanofi’s external engagement and policy shaping efforts with rare disease community. She brought a solid experience and demonstrated successes in patient advocacy and policy shaping in the rare disease space. Anne-Sophie is a major in genetic and...
last published: 13/Oct/24 14:15 GMT
